Loomis, Sayles & Company
APGE

Loomis, Sayles & Company’s Apogee Therapeutics APGE Stock Holding History

Loomis, Sayles & Company’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45M Sell
338,664
-24,117
-7% -$2.17M 0.06% 130
2026
Q1 		$30.5M Buy
362,781
+107,342
+42% +$7.8M 0.04% 165
2025
Q4 		$19.3M Buy
+255,439
New +$16.1M 0.02% 240

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Loomis, Sayles & Company's APGE Position: Q2 2026 in Review

Loomis, Sayles & Company reduced its Apogee Therapeutics (APGE) stake by 6.6% in Q2 2026, selling an estimated $2.17M and leaving 338,664 shares worth $45M. The position accounts for 0.06% of the portfolio, ranked #130.

Loomis, Sayles & Company first reported a position in APGE in Q4 2025 and has held it in 3 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Loomis, Sayles & Company held 338,664 shares of Apogee Therapeutics worth $45M as of Q2 2026.
  • Loomis, Sayles & Company sold 24,117 Apogee Therapeutics shares in Q2 2026, an estimated $2.17M.
  • Apogee Therapeutics made up 0.06% of Loomis, Sayles & Company's portfolio in Q2 2026, its #130 holding.
  • Loomis, Sayles & Company first reported a position in Apogee Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Loomis, Sayles & Company's 13F filing for Q2 2026, filed 14 Aug 2026.